Muriel Busson

1.7k total citations
35 papers, 1.4k citations indexed

About

Muriel Busson is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Muriel Busson has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 12 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Muriel Busson's work include Estrogen and related hormone effects (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Mitochondrial Function and Pathology (4 papers). Muriel Busson is often cited by papers focused on Estrogen and related hormone effects (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Mitochondrial Function and Pathology (4 papers). Muriel Busson collaborates with scholars based in France, United States and Morocco. Muriel Busson's co-authors include François Casas, Gwendal Lazennec, Gérard Cabello, Chantal Wrutniak‐Cabello, Pascal Seyer, Stéphanie Grandemange, Ángel Carazo, Laurence Pessemesse, André Pèlegrin and Marta Jarlier and has published in prestigious journals such as Nature Communications, PLoS ONE and Cancer Research.

In The Last Decade

Muriel Busson

35 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Muriel Busson France 23 727 468 280 259 154 35 1.4k
Anders Eriksson Sweden 19 1.2k 1.7× 316 0.7× 259 0.9× 121 0.5× 196 1.3× 36 2.1k
Samuel Seoane Spain 18 492 0.7× 361 0.8× 135 0.5× 121 0.5× 183 1.2× 38 1.1k
Jon Rosen United States 18 460 0.6× 462 1.0× 310 1.1× 328 1.3× 140 0.9× 24 1.6k
Christopher J. Molloy United States 29 1.7k 2.3× 733 1.6× 278 1.0× 159 0.6× 220 1.4× 60 2.8k
Louis Hornez France 17 784 1.1× 407 0.9× 161 0.6× 153 0.6× 205 1.3× 41 1.4k
Rosana Meyer United States 23 1.1k 1.5× 308 0.7× 187 0.7× 83 0.3× 220 1.4× 37 1.4k
Xiliang Zha China 26 1.1k 1.6× 273 0.6× 242 0.9× 79 0.3× 292 1.9× 78 1.8k
Hartwig Hennekes Germany 15 522 0.7× 232 0.5× 155 0.6× 170 0.7× 58 0.4× 25 1.3k
David V. Erbe United States 15 674 0.9× 240 0.5× 430 1.5× 88 0.3× 53 0.3× 25 1.3k
Mariko Kawakami United States 23 431 0.6× 416 0.9× 657 2.3× 90 0.3× 90 0.6× 52 1.4k

Countries citing papers authored by Muriel Busson

Since Specialization
Citations

This map shows the geographic impact of Muriel Busson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muriel Busson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muriel Busson more than expected).

Fields of papers citing papers by Muriel Busson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muriel Busson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muriel Busson. The network helps show where Muriel Busson may publish in the future.

Co-authorship network of co-authors of Muriel Busson

This figure shows the co-authorship network connecting the top 25 collaborators of Muriel Busson. A scholar is included among the top collaborators of Muriel Busson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muriel Busson. Muriel Busson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blache, Philippe, Lucile Canterel-Thouennon, Muriel Busson, et al.. (2019). A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth. Molecular Cancer Therapeutics. 18(8). 1386–1395. 10 indexed citations
2.
Lozza, Catherine, Alexandre Pichard, Julie Constanzo, et al.. (2019). Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. Clinical Cancer Research. 25(15). 4775–4790. 31 indexed citations
3.
4.
Boisguérin, Prisca, Christian Barrère, Anne Vincent, et al.. (2019). A novel therapeutic peptide targeting myocardial reperfusion injury. Cardiovascular Research. 116(3). 633–644. 14 indexed citations
5.
Jeitany, Maya, Cédric Leroy, M. Lafitte, et al.. (2018). Inhibition of DDR 1‐ BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Molecular Medicine. 10(4). 90 indexed citations
6.
Denis, Vincent, Muriel Busson, Lucile Canterel-Thouennon, et al.. (2017). Antibody targeting of claudin-1 as a potential colorectal cancer therapy. Journal of Experimental & Clinical Cancer Research. 36(1). 89–89. 48 indexed citations
7.
Leconet, Wilhem, Stanislas du Manoir, Clément Chevalier, et al.. (2016). Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clinical Cancer Research. 23(11). 2806–2816. 87 indexed citations
8.
Vives, Virginie, Christian Richard, Muriel Busson, et al.. (2015). Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation. Nature Communications. 6(1). 6218–6218. 52 indexed citations
9.
Arsic, Nikola, Gilles Gadéa, Ebba L. Lagerqvist, et al.. (2015). The p53 Isoform Δ133p53β Promotes Cancer Stem Cell Potential. Stem Cell Reports. 4(4). 531–540. 56 indexed citations
10.
Leconet, Wilhem, Christel Larbouret, Thierry Chardès, et al.. (2013). Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene. 33(47). 5405–5414. 81 indexed citations
11.
Docquier, Aurélie, Julien Savatier, Sandrine Bonnet, et al.. (2013). Negative Regulation of Estrogen Signaling by ERβ and RIP140 in Ovarian Cancer Cells. Molecular Endocrinology. 27(9). 1429–1441. 34 indexed citations
12.
Bossard, Carine, Muriel Busson, David Vindrieux, et al.. (2012). Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer. PLoS ONE. 7(9). e44787–e44787. 100 indexed citations
13.
Carazo, Ángel, Jonathan M. Levin, François Casas, et al.. (2012). Protein sequences involved in the mitochondrial import of the 3,5,3′‐L‐triiodothyronine receptor p43. Journal of Cellular Physiology. 227(12). 3768–3777. 14 indexed citations
14.
Badia, Éric, Aurélie Docquier, Muriel Busson, et al.. (2012). Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 132(1-2). 176–185. 9 indexed citations
15.
Seyer, Pascal, Stéphanie Grandemange, Pierrick Rochard, et al.. (2011). P43-dependent mitochondrial activity regulates myoblast differentiation and slow myosin isoform expression by control of Calcineurin expression. Experimental Cell Research. 317(14). 2059–2071. 36 indexed citations
16.
Boudousq, Vincent, Véronique Garambois, Caroline Mollévi, et al.. (2010). Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies. Journal of Nuclear Medicine. 51(11). 1748–1755. 20 indexed citations
17.
Bièche, Ivan, Carine Chavey, Catherine Andrieu, et al.. (2007). CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocrine Related Cancer. 14(4). 1039–1052. 145 indexed citations
18.
19.
Duong, Vanessa, Raphaël Margueron, Nathalie Boulle, et al.. (2005). ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene. 25(12). 1799–1806. 67 indexed citations
20.
Rodier, Anne, Pierrick Rochard, Cyril Berthet, et al.. (2001). Identification of functional domains involved in BTG1 cell localization. Oncogene. 20(21). 2691–2703. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anders Eriksson Breakdown of academic impact, for papers by Samuel Seoane Breakdown of academic impact, for papers by Jon Rosen Breakdown of academic impact, for papers by Christopher J. Molloy Breakdown of academic impact, for papers by Louis Hornez Breakdown of academic impact, for papers by Rosana Meyer Breakdown of academic impact, for papers by Xiliang Zha Breakdown of academic impact, for papers by Hartwig Hennekes Breakdown of academic impact, for papers by David V. Erbe Breakdown of academic impact, for papers by Mariko Kawakami
Rankless by CCL
2026